{"id":35,"date":"2020-05-14T23:08:00","date_gmt":"2020-05-14T15:08:00","guid":{"rendered":"https:\/\/flcube.com\/?p=35"},"modified":"2024-11-23T22:30:07","modified_gmt":"2024-11-23T14:30:07","slug":"cuban-chinese-pharma-synergy-joint-rd-and-sales-initiative-targets-usd-24-53-billion-in-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35","title":{"rendered":"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales"},"content":{"rendered":"\n<p>In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered into a letter of intent with BioCubaFarma, Cuba&#8217;s leading state-owned pharmaceutical company. This strategic alliance is aimed at joint research and development (R&amp;D), manufacturing, and sales of cutting-edge pharmaceutical products in China, with a particular focus on biologics. The agreement is also set to foster technological and personnel exchanges, enriching the collaborative framework between the two entities.<\/p>\n\n\n\n<p>This partnership is instrumental in advancing Guangzhou Pharma&#8217;s strategic evolution from a generics-centric model to one that emphasizes high-value innovative pharmaceuticals. The company has set an ambitious sales target of RMB 150 billion (approximately USD 24.53 billion) by 2020, underpinned by this transformative deal. The joint venture will establish a robust biologic R&amp;D platform, paving the way for the introduction of a suite of high-tech innovative biologics and biosimilars from BioCubaFarma into the Chinese market.<\/p>\n\n\n\n<p>BioCubaFarma, in turn, stands to gain from the technological cross-fertilization and enhanced industrial capabilities that this collaboration promises, marking a win-win scenario for both parties. <a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[524],"class_list":["post-35","post","type-post","status-publish","format-standard","hentry","category-company","tag-guangzhou-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered into a letter of intent with BioCubaFarma, Cuba&#039;s leading state-owned pharmaceutical company. This strategic alliance is aimed at joint research and development (R&amp;D), manufacturing, and sales of cutting-edge pharmaceutical products in China, with a particular focus on biologics. The agreement is also set to foster technological and personnel exchanges, enriching the collaborative framework between the two entities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-14T15:08:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T14:30:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales\",\"datePublished\":\"2020-05-14T15:08:00+00:00\",\"dateModified\":\"2024-11-23T14:30:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35\"},\"wordCount\":194,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Guangzhou Pharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35#respond\"]}],\"copyrightYear\":\"2020\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35\",\"name\":\"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2020-05-14T15:08:00+00:00\",\"dateModified\":\"2024-11-23T14:30:07+00:00\",\"description\":\"In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered into a letter of intent with BioCubaFarma, Cuba's leading state-owned pharmaceutical company. This strategic alliance is aimed at joint research and development (R&D), manufacturing, and sales of cutting-edge pharmaceutical products in China, with a particular focus on biologics. The agreement is also set to foster technological and personnel exchanges, enriching the collaborative framework between the two entities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales - Insight, China&#039;s Pharmaceutical Industry","description":"In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered into a letter of intent with BioCubaFarma, Cuba's leading state-owned pharmaceutical company. This strategic alliance is aimed at joint research and development (R&D), manufacturing, and sales of cutting-edge pharmaceutical products in China, with a particular focus on biologics. The agreement is also set to foster technological and personnel exchanges, enriching the collaborative framework between the two entities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35","og_locale":"en_US","og_type":"article","og_title":"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=35","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2020-05-14T15:08:00+00:00","article_modified_time":"2024-11-23T14:30:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales","datePublished":"2020-05-14T15:08:00+00:00","dateModified":"2024-11-23T14:30:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35"},"wordCount":194,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Guangzhou Pharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35#respond"]}],"copyrightYear":"2020","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35","url":"https:\/\/flcube.com\/?p=35","name":"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2020-05-14T15:08:00+00:00","dateModified":"2024-11-23T14:30:07+00:00","description":"In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered into a letter of intent with BioCubaFarma, Cuba's leading state-owned pharmaceutical company. This strategic alliance is aimed at joint research and development (R&D), manufacturing, and sales of cutting-edge pharmaceutical products in China, with a particular focus on biologics. The agreement is also set to foster technological and personnel exchanges, enriching the collaborative framework between the two entities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cuban-Chinese Pharma Synergy: Joint R&amp;D and Sales Initiative Targets USD 24.53 Billion in Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35\/revisions"}],"predecessor-version":[{"id":14531,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35\/revisions\/14531"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}